PLGA/TCP composite scaffold incorporating bioactive phytomolecule icaritin for enhancement of bone defect repair in rabbits
PLGA/TCP composite scaffold incorporating bioactive phytomolecule icaritin for enhancement of bone defect repair in rabbits
复制标题
DOI：
10.1016/j.actbio.2013.01.024
复制
发表时间：
2013-05-01
影响因子：
9.7
通讯作者：
Qin, L.
中科院分区：
文献类型：
--
作者：
Chen, S. -H.;Lei, M.;Qin, L.
骨缺损修复在骨科临床中具有挑战性。对于大骨缺损的治疗，骨移植仍然是大多数外科医生的首选方法，因为它填充空间并提供支持以增强生物骨修复。由于治疗剂对于促进骨愈合是期望的，本研究设计开发这样的生物活性复合支架（PLGA/TCP/ICT），其由聚丙交酯-共-乙交酯（PLGA）和磷酸三钙（TCP）作为基本载体制成，掺入植物分子淫羊藿素（ICT），即，一种新的成骨外源性生长因子。PLGA/TCP/ICT支架分别为PLGA/TCP（对照组）和PLGA/TCP串联低、中、高剂量ICT（LICT/MICT/HICT组）。为了评价这些具有缓慢释放成骨ICT的生物活性支架的体内成骨和血管生成潜力，作者在兔中建立了12 mm尺骨骨缺损模型。术后2、4、8周X线片和高分辨率外周定量计算机断层扫描结果显示，植入PLGA/TCP/ICT支架的骨缺损内新生骨较多，尤其是PLGA/TCP/MICT支架。第4周和第8周的组织学结果也表明，PLGA/TCP/ICT组，特别是PLGA/TCP/MICT组，有更多的新矿化骨，相应地有更多的新血管长入。这些发现可能为这种创新的生物活性支架与适量的促骨植物分子ICT结合作为临床应用的现成产品的潜在临床验证奠定了良好的基础。(C)2013 Acta Materialia Inc.由爱思唯尔有限公司出版。保留所有权利。
Bone defect repair is challenging in orthopaedic clinics. For treatment of large bone defects, bone grafting remains the method of choice for the majority of surgeons, as it fills spaces and provides support to enhance biological bone repair. As therapeutic agents are desirable for enhancing bone healing, this study was designed to develop such a bioactive composite scaffold (PLGA/TCP/ICT) made of polylactide-co-glycolide (PLGA) and tricalcium phosphate (TCP) as a basic carrier, incorporating a phytomolecule icaritin (ICT), i.e., a novel osteogenic exogenous growth factor. PLGA/TCP/ICT scaffolds were fabricated as PLGA/TCP (control group) and PLGA/TCP in tandem with low/mid/high-dose ICT (LICT/MICT/HICT groups, respectively). To evaluate the in vivo osteogenic and angiogenic potentials of these bioactive scaffolds with slow release of osteogenic ICT, the authors established a 12 mm ulnar bone defect model in rabbits. X-ray and high-resolution peripheral quantitative computed tomography results at weeks 2, 4 and 8 post-surgery showed more newly formed bone within bone defects implanted with PLGA/TCP/ICT scaffolds, especially PLGA/TCP/MICT scaffold. Histological results at weeks 4 and 8 also demonstrated more newly mineralized bone in PLGA/TCP/ICT groups, especially in the PLGA/TCP/MICT group, with correspondingly more new vessel ingrowth. These findings may form a good foundation for potential clinical validation of this innovative bioactive scaffold incorporated with the proper amount of osteopromotive phytomolecule ICT as a ready product for clinical applications. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.